Yulin Qin
About Yulin Qin
Yulin Qin is the Head of Biometrics and Data Science, China at Bristol Myers Squibb, with over 15 years of experience in biostatistics and data science, having held senior roles at AstraZeneca, Shire, inVentiv Health Commercial, and UnitedHealth Group.
Title
Yulin Qin is the Head of Biometrics and Data Science, China at Bristol Myers Squibb. This role places Yulin Qin at the forefront of integrating biometrics and data science in the company's initiatives within the China region.
Education and Expertise
Yulin Qin holds a Doctor of Philosophy (PhD) in Biostatistics and a Master's Degree in Statistics from the University of Cincinnati. Additionally, Yulin Qin achieved a Bachelor's degree in Mathematics from Suzhou University. This extensive academic background lays a strong foundation for his expertise in biostatistics and data science.
Professional Background
Yulin Qin has accumulated over 15 years of experience in the field of biostatistics and data science. He has held roles in multiple major organizations, including AstraZeneca as Statistician Director - Biostatistics Head of Oncology from 2016 to 2021, Shire as Manager Biostatistics from 2015 to 2016, inVentiv Health Commercial as Senior Biostatistician from 2011 to 2015, UnitedHealth Group as Senior Statistical Analyst from 2009 to 2011, and Procter & Gamble as Biostatistician from 2007 to 2009.
Achievements
In his role at AstraZeneca, Yulin Qin led significant advancements in cancer research through his leadership in biostatistics for oncology. This experience underscores his contributions to crucial healthcare and pharmaceutical projects, demonstrating his impact in both the U.S. and China.
Global Perspective and Leadership
Yulin Qin brings a global perspective to his work, having served in senior roles in both the United States and China. He has a proven track record of leadership in the field, managing teams and projects across various organizations. His in-depth understanding of statistical methodologies and their application in clinical trials and drug development is a testament to his expertise.